Central Retinal Vein Occlusion

Overview of diagnosis and treatment of central retinal vein occlusion.

What is a Central Retinal Vein Occlusion?

The inner layers of the retina receive their blood supply from the central retinal artery. The blood returns to the heart through the central retinal vein. Both vessels enter the eye through a small opening in the middle of the optic nerve. Either because this opening shrinks or because the artery hardens or because of circulations problems, the central retinal vein can become partially or completely occluded. When a patient develops a central retinal vein occlusion (CRVO), they lose some or most of their central vision. The photograph of the retina on the right is of an eye with 20/50 visual acuity with a central retinal vein occlusion for 6 weeks. The retinal veins dilate and there are retinal hemorrhages. Patients often develop swelling of the central retina-cystoid macular edema--causing some of the vision loss. Without treatments, 25% of eyes improve, 50% stabilize, and 25% worsen.

Lucentis for Central Retinal Vein Occlusion

Monthly Lucentis therapy is also helpful in improving vision in patients with central retinal vein occlusion and macular edema. Without treatment about 15 percent of have visual improvement. With treatment about 50 percent of patients have improved vision. Long term follow-up show that at 4 years, a little over half of the patients with central retinal vein occlusion require continued treatment to maintain the visual benefit.


Eylea for Central Retinal Vein Occlusion

Monthly Eylea therapy is also helpful in improving vision in patients with central retinal vein occlusion and macular edema. Without treatment about 15 percent of have visual improvement. With treatment about 60 percent of patients have improved vision.


Central Retinal Vein Occlusion NEWS

Below are current articles from a Google News Feed on Central Retinal Vein Occlusion

Focus on Eyes: Vision loss and retinal vein occlusion  Florida Today

When a retinal vein is blocked, it can lead to severe loss of vision.

Increase in choroidal thickness seen after CPAP therapy  Healio

Patients with obstructive sleep apnea syndrome who underwent continuous positive airway pressure therapy experienced an increase in choroidal thickness ...

2018-2023 Global Virtual Prototype Market Overview and Market Application  The Flatland Post

The Global Global Virtual Prototype Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023: Virtual Prototype Market Report ...

Anti-VEGF treatment of macular edema associated with retinal vein occl | OPTH  Dove Medical Press

Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in clinical practice (ECHO study report 2) J ...

Retinal Vein Occlusion Market Rising Demand Seen in Healthcare at a CAGR of 11.2% by 2023 | By Types Branch Retinal Artery Occlusion, Central Retinal Vein Occlusion – Says MRFR |  Medgadget

Market Research Future published a research report on “Global Retinal Vein Occlusion Market” to track and analyses developments which are competitive in.

Retinal Vein Occlusion Market Size and Trend by Branch and Central Retinal Vein Occlusion Type, Etc. Types and Forecast to 2023 |  Medgadget

Glaucoma is a condition where the eye pressure causes damage to the optic nerve. The increasing number of patients with glaucoma is leading the retinal vein ...

Retinal Vein Occlusion Market Leading Players - Allergan, Bayer, Bristol-Myers Squibb, Regeneron Pharmaceuticals & others, etc  openPR

Retinal Vein Occlusion Market Report Examines the Market position and viewpoint of the market globally, from various angles, such as key players, ...

Why Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Could be Ready to Star in the Speculative Spotlight  FDA Headlines

Dec 7, 2018 | Business. Why Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Could be Ready to Star in the. Regeneron Pharmaceuticals Inc ...

Regeneron (REGN) Rides on Eylea and Dupixent's Performance  Zacks.com

Solid performance of approved drugs like Eylea and Dupixent along with an encouraging pipeline progress improve Regeneron's (REGN) market position.

First Republic Investment Management Inc. Reduces Stake in Regeneron Pharmaceuticals Inc (REGN)  Fairfield Current

First Republic Investment Management Inc. decreased its stake in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 9.6% during the 3rd quarter, ...

Avastin as effective as Eylea for treating central retinal vein occlusion: Clinical trial shows use of either drug improved vision and had few side effects  Science Daily

Monthly eye injections of Avastin (bevacizumab) are as effective as the more expensive drug Eylea (aflibercept) for the treatment of central retinal vein occlusion ...

Mix of old and new sees ophthalmology updates! Flourish  Insight News

A unique formula and talented line-up of presenters has seen Ophthalmology Updates! go from strength-to-strength during its short history. In part two of his ...

Retinal Vein Occlusion Market 2018 Highlights | By Types – Branch Retinal Artery Occlusion, Central Retinal Vein Occlusion | Top 10 Player Analysis by 2023 - Press Release  Digital Journal

Retinal Vein Occlusion Market Information: By Condition (Non-Ischemic and Ischemic), Diagnosis (Optical Coherence Tomography), Treatment and End-User ...

Treatment arms for CRVO yield no difference in visual acuity results  Healio

BOSTON — Dexamethasone implant, ranibizumab injections or a combination of the two each yielded no statistically significant difference in visual acuity or ...

Bevacizumab as effective as aflibercept for central retinal vein occlusion  The Pharmaceutical Journal

Bevacizumab is frequently used off-label for treating macular oedema resulting from central retinal vein occlusion (CRVO), despite a lack of supporting data.

Central Retinal Vein Occlusion (CRVO)  News-Medical.net

Central retinal vein occlusion (CRVO) is the most common disease of the retinal vessels. It refers to a blockage of the vein draining the retinal tissue at the back ...

Ozurdex for retinal vein occlusion approved in China  Healio

The Chinese Food and Drug Administration has approved Ozurdex to treat adults with macular edema after branch retinal vein occlusion or central retinal vein ...

IOP spikes more likely after treatment in certain patients  Healio

Mild to moderate IOP spikes were seen after multiple injections of Ozurdex for treatment of uveitis, diabetic macular edema and retinal vein occlusion, but ...

Retinal Vein Occlusion (RVO) Market to Observe Strong Growth at a CAGR of 11.2% till 2023 | by MRFR |  Medgadget

Market Research Future (MRFR)'s study reveals that the “Global Retinal Vein Occlusion Market”, the report offer detailed Analysis about the Top Trends and.

Central retinal vein occlusion (CRVO): Types, causes, symptoms, and treatment  Bel Marra Health

Central retinal vein occlusion (CRVO) refers to a medical condition of the eye where main vein of the retina has become blocked.

Surgical eye robot performs precision injection in patient with retinal vein occlusion  Medical Xpress

Eye surgeons at University Hospitals Leuven have been the first to use a surgical robot to operate on a patient with retinal vein occlusion. The robot uses a ...

KOD Catches Eyes, MRNS On Watch, Mark Your Calendar For AQST  Nasdaq

Gained 22.37% to close Thursday's trading at $9.30. The Company went public on the Nasdaq Global Market on October 4, 2018, offering its shares at a.

Regeneron Pharmaceuticals (REGN) Stock Rating Upgraded by BidaskClub  Fairfield Current

Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by equities research analysts at BidaskClub from a “hold” rating to a “buy” rating in a research ...

Case Report Highlights Acute Central Retinal Vein Occlusion in Scleroderma Patient  Scleroderma News

Researchers in Saudi Arabia at King Fahd Hospital of the University and the University of Dammam reported a case of a male patient with scleroderma who was ...

CRYSTAL study shows good results of personalized anti-VEGF treatment regimen in CRVO  Healio

Two-year results of the CRYSTAL study show that an as-needed medication regimen with frequent monitoring can reduce the number of anti-VEGF injections ...

Comparison between intravitreal bevacizumab and posterior sub-tenon in | OPTH  Dove Medical Press

Comparison between intravitreal bevacizumab and posterior sub-tenon injection of triamcinolone acetonide in macular edema secondary to retinal vein ...

Ozurdex® (dexamethasone 0.7mg) now available for millions of patients in China with macular edema secondary to retinal vein occlusion  Markets Insider

--An estimated 7.4 million people in China are living with this sight-threatening conditioni,ii,iii --. DUBLIN, March 22, 2018 /PRNewswire/ -- Today, Allergan plc ...

SCORE2: Visual acuity results with bevacizumab non-inferior to aflibercept as treatment for macular edema due to CRVO  Healio

The SCORE2 study showed that intravitreal bevacizumab is non-inferior to aflibercept as a treatment for macular edema due to central retinal or hemiretinal vein ...

Branch retinal vein occlusion (BRVO) recovery: Causes, symptoms, and treatment  Bel Marra Health

Branch retinal vein occlusion or BRVO is often referred to as an “eye stroke” and can impact a person's ability to see. The degree of vision loss varies in each ...

Clearside Biomedical Provides Update on Two Phase 3 Clinical Trials of CLS-TA in Retinal Vein Occlusion  GlobeNewswire

ALPHARETTA, Ga., March 06, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing ...

Commonwealth of Pennsylvania Public School Empls Retrmt SYS Has $2.57 Million Holdings in Regeneron Pharmaceuticals Inc (NASDAQ:REGN)  Fairfield Current

Commonwealth of Pennsylvania Public School Empls Retrmt SYS cut its holdings in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 21.5% ...

Oppenheimer Reiterates $440.00 Price Target for Regeneron Pharmaceuticals (REGN)  Fairfield Current

Oppenheimer set a $440.00 target price on Regeneron Pharmaceuticals (NASDAQ:REGN) in a research report released on Sunday morning. The firm currently ...

Anti-VEGF Therapy Before Steroids for Retinal Vein Occlusion  Medscape

NICE, France — Aflibercept and ranibizumab are safer than dexamethasone intravitreal implants for the treatment of central retinal vein occlusion, a new study ...

Cheap Avastin as effective as Eylea in CRVO  European Biotechnology

A study conducted by an NIH institute proves Roche's Avastin is as effective as Regeneron's Eylea, a drug that costs 30 times more than Roche's antibody.

Safety, Tolerability Increases Post-Bevacizumab Injection in Intraocular Pressure  MD Magazine

New research has shown that increased IOP is tolerable to corneal endothelium, and safe for most patients' eyes despite immediate increases post-injection.

Effect of intravitreal ranibizumab on serous retinal detachment in bra | OPTH  Dove Medical Press

Effect of intravitreal ranibizumab on serous retinal detachment in branch retinal vein occlusion Emine Dogan,1 Ozkan Sever,2 Burcin Köklü Çakir,1 Erkan Celik1 ...

Clearside Biomedical Announces Completion of Patient Enrollment in First of Two Phase 3 Clinical Trials of CLS-TA in Retinal Vein Occlusion  GlobeNewswire

ALPHARETTA, Ga., June 13, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing ...

Head to Head Survey: Clearside Biomedical (CLSD) vs. KemPharm (KMPH)  Fairfield Current

Clearside Biomedical (NASDAQ:CLSD) and KemPharm (NASDAQ:KMPH) are both small-cap medical companies, but which is the superior investment? We will ...

Should We WAVE Goodbye to Laser?  Medscape

This study helps answer a common clinical question as to whether peripheral laser to areas of retinal ischemia improves vision and reduces injection burden in ...

RELATE study: Increased ranibizumab, laser yield minimal benefits  Healio

BOSTON — An increased dose of ranibizumab offered no added benefit in eyes with retinal vein occlusion, according to a study presented here. Additionally ...

Regeneron Pharmaceuticals Inc (REGN) Expected to Post Earnings of $5.61 Per Share  Fairfield Current

Equities research analysts expect Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to post earnings per share of $5.61 for the current quarter, according to ...

Biosimilar Ranibizumab Effective in Treating RVO in a Real-World Setting  The Center for Biosimilars

In India, Razumab, manufactured by Intas Pharmaceuticals, was approved as a similar biologic to ranibizumab in 2015; the retrospective study RE-ENACT ...

Laser Speckle Flowgraphy Can Assist in CRVO Prognosis  Medscape

Laser speckle flowgraphy may offer a noninvasive method of assessing ocular blood flow in patients with central retinal vein occlusion (CRVO), according to a ...

VIDEO: SCORE2 and LEAVO trials underway to compare CRVO treatments  Healio

KOLOA, Hawaii ― At Hawaiian Eye 2017, Michael S. Ip, MD, updates colleagues on the U.S.-based SCORE2 trial and the U.K.-based LEAVO trial, both of which ...

New gene therapy for vision loss proven safe in humans  Medical Xpress

In a small and preliminary clinical trial, Johns Hopkins researchers and their collaborators have shown that an experimental gene therapy that uses viruses to ...

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Holdings Reduced by Commonwealth of Pennsylvania Public School Empls Retrmt SYS  Fairfield Current

Commonwealth of Pennsylvania Public School Empls Retrmt SYS lessened its position in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by ...

Switching to Aflibercept Demonstrates Improvement in VA, CST for Poor Responders to Bevacizumab in SCORE2  MD Magazine

Those who were switched to aflibercept improved 9 letters of VA, and 110 µm in CST from months 6 to 12.

High systolic BP affects your retina and may lead to complete vision loss  Economic Times

Constant fluctuations in the systolic pressure can lead to many major eye complications.

Disorganization of Retinal Inner Layers Linked to Visual Acuity Prognoses  MD Magazine

A new study suggests patients with disorganized retinal inner layers see lesser levels of visual acuity improvement after therapy.

Complications After Intravitreal Injection Aggravate  Medscape

VANCOUVER, Canada — Clusters of inflammatory responses after intravitreal injections have unnerved some specialists, who will share their experiences and ...

Altris.AI – The New Era of Retinal Diagnosis is Coming  Business Wire

Altris.AI (Altris, Inc) announced it has signed an agreement with a South Korean ophthalmic and optical medical equipment manufacturer Huvitz Co., Ltd.

FDA OKs Aflibercept (Eylea) for All Retinal Vein Occlusions  Medscape

The US Food and Drug Administration (FDA) has expanded the indication of aflibercept (Eylea, Regeneron) injection to include all forms of macular edema after ...

Retinal artery and vein thrombotic occlusion during pregnancy: markers | OPTH  Dove Medical Press

Retinal artery and vein thrombotic occlusion during pregnancy: markers for familial thrombophilia and adverse pregnancy outcomes Will S Kurtz,1 Charles J ...

Integrated results from the COPERNICUS and GALILEO studies | OPTH  Dove Medical Press

Integrated results from the COPERNICUS and GALILEO studies Amelie Pielen,1,2 W Lloyd Clark,3 David S Boyer,4 Yuichiro Ogura,5 Frank G Holz,6 ...

Branch Retinal Artery Occlusion (BRAO): Causes, Symptoms, Diagnosis, and Treatment  Bel Marra Health

Branch retinal artery occlusion or BRAO is a vision-related disease-causing long-term vision problems. It is caused due to reduced or blocked blood flow.

Bayer files eye drug Eylea for new use in EU  PMLiVE

Bayer has filed an application to extend the indications of its ophthalmic drug Eylea in Europe to include use in patients with branch retinal vein occlusion ...

Risk Factors for Retinal Vein Occlusion  Medscape (subscription)

Is there a link between traditional risk factors for vascular disease and retinal vein occlusion?

Retinal Vein Occlusion Associated With Stroke  Medscape

Retinal vein occlusion (RVO) is significantly associated with stroke development, according to a recent study. Although the investigators adjusted for potential ...

Putnam FL Investment Management Co. Boosts Holdings in Regeneron Pharmaceuticals Inc (NASDAQ:REGN)  PressOracle

Putnam FL Investment Management Co. raised its stake in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 1.6% in the 3rd quarter, according to ...

Retinal Vein Occlusion Therapeutics Market Share Worldwide Industry Growth, Size, Statistics, Opportunities & Forecasts up to 2023  News by Sharp Reports

An analysis of Retinal Vein Occlusion Therapeutics market has been provided in the latest report launched by Market Study Report that primarily focuses on the ...

NICE backs Bayer's Eylea as first-line BRVO treatment  PMLiVE

Bayer's Eylea (aflibercept) has been recommended for use on the NHS in England and Wales as a first-line treatment for adults with branch retinal vein ...

Saving the sight of millions  Medical Xpress

Two eye surgeons (ophthalmologists) have written a first-of-its-kind book to save the sight of millions of patients around the world by making eye injections ...

Head-To-Head Survey: Clearside Biomedical (CLSD) & KemPharm (KMPH)  Fairfield Current

Clearside Biomedical (NASDAQ:CLSD) and KemPharm (NASDAQ:KMPH) are both small-cap medical companies, but which is the superior investment? We will ...

Biosimilars Reported Safe, Effective for Retinal Disease  Medscape

CHICAGO — Biosimilars made in India are as safe and effective for retinal vascular diseases as the American-made originator drugs, but cost about 40% less, ...

Genentech Unveils Positive Phase II Results for the First-Ever Eye Implant to Achieve Sustained Delivery of a Biologic Medicine to Treat People With Wet Age-Related Macular Degeneration (AMD)  Business Wire

Genentech's investigational Port Delivery System with ranibizumab (PDS) is a small, refillable device, slightly longer than a grain of rice, surgically implanted in ...

Clearside Scraps Xipere for RVO after Phase III Failure; Shares Tumble 58%  Genetic Engineering & Biotechnology News

Clearside Biomedical lost more than half its stock value today after it said it was scrapping clinical development of its lead candidate Xipere (formerly ...

Revealing the retina: Graphene corneal contact lens provides robust, irritation-free topographic electroretinography  Phys.org

Our vision can be damaged or lost by damage to the retina—a sensory membrane lining the back of the eye that senses light, converting the image formed into ...

Eye strokes (retinal artery occlusion): Symptoms, causes, and treatment  Bel Marra Health

Eye strokes can come one suddenly and result in partial or complete loss of vision. Learn about cause, risk factors and treatment options.

Eylea Competition Coming But Pipeline Could Maintain Growth For Regeneron  Seeking Alpha

Eylea represents a significant portion of revenue and will face upcoming competition, which could slow Regeneron sales growth over the coming years.

Similar Efficacy for Key Anti-VEGF Agents in Macular Edema  Medscape

The SCORE2 trial shows that bevacizumab and aflibercept may produce similar short-term outcomes. Here is a closer look at its results.

High Blood Pressure, High Cholesterol May Be Associated With Retinal Vascular Disease  Science Daily (press release)

High blood pressure and high cholesterol levels appear to be risk factors for retinal vein occlusion, a condition that causes vision loss, according to a new article.

Easier treatment for blinding eye disease shows promise in clinical trial  Science Daily

A new study shows that an implantable delivery system for a widely used medication to treat a blinding eye disease has enabled some patients to go 15 months ...

Biosimilars for bevacizumab and ranibizumab show promise for retinal diseases  Healio

VANCOUVER, British Columbia — Data for two new biosimilars for ranibizumab and bevacizumab, currently available in India, show the treatments are safe and ...

Topical Squalamine 0.2% and Intravitreal Ranibizumab 0.5 mg as Combination Therapy for Macular Edema Due to Branch and Central Retinal Vein Occlusion: An Open-Label, Randomized Study  Healio

Ophthalmic Surgery, Lasers and Imaging Retina | BACKGROUND AND OBJECTIVE:To evaluate the effects of squalamine (OHR-102; Ohr Pharmaceuticals, ...

The eye jab that can banish blind spots  Daily Mail

Clive Woodington had Central Retinal Vein Occlusion (CRVO), a distressing condition that can lead to blindness in the affected eye.

Retinal Vein Occlusion Market expected to grow at a CAGR of 11.2% By 2023  openPR

Market Research Future Recently Added Premium Research Reports on ” Retinal Vein Occlusion Market Research Report - Global Forecast till 2023” Which ...

Allergan Receives Approval for Ozurdex® (Dexamethasone Intravitreal Implant 0.7 mg) in China for the Treatment of Retinal Vein Occlusion (RVO)  PR Newswire

DUBLIN, Oct. 30, 2017 /PRNewswire/ -- Allergan plc (NYSE: AGN) announced today that it has received an Imported Drugs License (IDL) from the Chinese Food ...

Clearside Biomedical: Buy Or Sell Before 2018 Catalysts  Seeking Alpha

The 8-week data from the first phase 3 trial (SAPPHIRE) in treating macular edema due to retinal vein occlusion is expected in Q4 (a big binary event for the st.

New Stairway Study Data Shows Potential for Extended Durability with Faricimab in Wet Age-Related Macular Degeneration (AMD)  Business Wire

Faricimab – the first bispecific antibody designed for the eye – dosed every four months demonstrated sustained vision outcomes compared to monthly ...

Evaluation of contrast sensitivity and other visual function outcomes | OPTH  Dove Medical Press

Evaluation of contrast sensitivity and other visual function outcomes in diabetic macular edema patients following treatment switch to aflibercept from ...

RETINA-AI Releases the First Artificial Intelligence Mobile App for Eye-Care Providers: Fluid Intelligence by RETINA-AI  PR Newswire

HOUSTON, July 17, 2018 /PRNewswire/ -- RETINA-AI has developed and released the first Artificial Intelligence mobile app for eye-care providers. This app ...

Regeneron's Eylea Gets FDA Nod for Wet AMD as a 12-Week Dose  Zacks.com

Regeneron Pharmaceuticals (REGN) gets the FDA approval for the label expansion of its lead drug, Eylea as a treatment for wet AMD with a modified 12-week ...

Bevacizumab, Ranibizumab Biosimilars Proven Effective, Safe for Retina Diseases  MD Magazine

The introduction of biosimilars into retinal vascular disease care has been proven to be a win-win for physicians and patients alike. New intravitreal biosimilar ...

Victrex PLC (LON:VCT) Was Downgraded by Berenberg; Allergan Plc Ordinary Shares (AGN) Shorts Increased By 25.7%  The FinExaminer

Berenberg cut Victrex PLC (LON:VCT)'s stock to a Hold rating. The ratings change was issued in a an analyst note today. The financial firm currently has a GBX ...

Visual acuity loss associated with excessive "dry macula" in exudative | OPTH  Dove Medical Press

Visual acuity loss associated with excessive "dry macula" in exudative age-related macular degeneration Hidenori Takahashi,1–3 Yuji Inoue,1,2 Xue Tan,2,3 ...

Gathering of minds at ANZGS 2018  Insight News

LEWIS WILLIAMS joined the foremost glaucoma experts in the country at the Australian and New Zealand Glaucoma Society (ANZGS) in February. Part one of ...

Fast Action Can Save Sight if Retina Is Detached or Blocked  New York Times

Modern treatments can do wonders if they are begun before the damage to the eye is irreversible.

Monthly, PRN doses of ranibizumab similarly effective in RVO  Healio

TORONTO — As-needed and monthly ranibizumab dosing regimens yielded similar visual acuity gains in patients with retinal vein occlusion who reached a ...

A potential new way to treat some of the most common blinding diseases  Science Daily

Many eye diseases exhibit increased permeability of blood vessels in the macular portion of the retina leading to abnormal fluid accumulation and vision loss.

Topical timolol-dorzolamide combined with anti-VEGF could better treat macular edema  Healio

PHILADELPHIA – An ongoing study suggests that topical timolol-dorzolamide can reduce central subfield thickness in patients with persistent macular edema ...

Neovascular Glaucoma (NVG): Causes, Symptoms, and Treatment  Bel Marra Health

NVG is a rare condition that is most prevalent in elderly patients. The treatment for NVG is extremely difficult, but the condition is not life-threatening.

Contrasting Clearside Biomedical (CLSD) & KemPharm (KMPH)  PressOracle

Clearside Biomedical (NASDAQ:CLSD) and KemPharm (NASDAQ:KMPH) are both small-cap medical companies, but which is the better stock? We will ...

Regeneron Gains on Eylea, Dupixent and Pipeline Progress  Nasdaq

Shares of Regeneron Pharmaceuticals Inc . REGN have gained 3.2% in the year so far against a decline of 5.9% for the industry . Tarrytown,.

Vascular Endothelial Growth Factor B Market Forecast – Industry Value, Market Size, Top Companies and General Trends for 2018-2025  MediaTrig

Global Vascular Endothelial Growth Factor B Market report describes elements such as dominating companies, types, applications, classification, size, SWOT ...

RETINA-AI Releases Android Version of Fluid-Intelligence -- World's First Mobile Artificial Intelligence App for Eye Care Providers  BioSpace

Published: Oct 22, 2018. HOUSTON, Oct. 22, 2018 /PRNewswire/ -- RETINA-AI has released an Android version of its app Fluid-Intelligence, the world's first ...

CRAO and Stroke Risk: Is Neurological Evaluation Warranted?  Medscape

Patients with central retinal artery occlusion may be at an increased risk for stroke and may benefit from prompt neurological evaluation, according to a new ...

Intravitreal anti-VEGF use not tied to systemic adverse events  Medical Xpress

(HealthDay)—Intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment is not associated with increased risk of systemic adverse events for ...

Placenta Growth Factor Market Research and Developments 2018 to 2025  Stetson Reporter

“Global Placenta Growth Factor Market Insights, Forecast To 2025” presents an in-depth assessment of the Placenta Growth Factor Market providing quantitative ...

Drug and Device News December 2018  P&T Community

Approvals, new indications, regulatory activities, and more.

FDA Approves Genentech's Lucentis (ranibizumab injection) 0.3 mg Prefilled Syringe for Diabetic Macular Edema and Diabetic Retinopathy  Business Wire

First and only prefilled syringe treatment option FDA-approved to treat all forms of diabetic retinopathy in people with or without diabetic macular edema (DME) ...

» Load more